Detalles de la búsqueda
1.
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
Breast Cancer Res Treat
; 179(1): 67-77, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31562570
2.
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
Breast Cancer Res Treat
; 179(3): 769, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31734822
3.
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Breast Cancer Res Treat
; 180(3): 635-646, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32130619
Resultados
1 -
3
de 3
1
Próxima >
>>